Department of Inborn Errors of Metabolism and Paediatrics, Institute of Mother and Child, 01-211 Warsaw, Poland.
Birmingham Children's Hospital, Birmingham B4 6NH, UK.
Medicina (Kaunas). 2021 Feb 2;57(2):128. doi: 10.3390/medicina57020128.
Methylmalonic aciduria is treated with a natural protein-restricted diet with adequate energy intake to sustain metabolic balance. Natural protein is a source of methylmalonic acid precursors, and intake is individually modified according to the severity and clinical course of the disease. The experience and approach to MMA treatment in European centers is variable with different amounts of natural protein and precursor-free l-amino acids being prescribed, although the outcome appears independent of the use of precursor-free l-amino acids. Further long-term outcome data is necessary for early treated patients with MMA. This case study, a woman with MMA followed from birth to the age of 35 years, including pregnancy, illustrates the long-term course of the disease and lifetime changes in dietary treatment. A low natural protein diet (1.5 g-1.0 g/kg/day) was the foundation of treatment, but temporary supplementation with precursor-free l-amino acids, vitamin-mineral mixture, and energy supplements were necessary at different timepoints (in childhood, adolescence, adulthood and pregnancy). Childhood psychomotor development was slightly delayed but within the normal range in adulthood. There were few episodes of metabolic decompensation requiring IV glucose, but at age 27 years, she required intensive care following steroid treatment. In pregnancy, she remained stable but received intensive biochemical and medical follow-up. This successful long-term follow-up of a patient with MMA from childhood, throughout pregnancy, delivery, and postpartum confirms that careful clinical, biochemical, and dietetic monitoring is crucial to ensure a favourable outcomes in MMA. Personalized treatment is necessary according to the individual clinical course. Knowledge about long-term treatment and clinical outcome is important information to influence future MMA clinical guidelines.
甲基丙二酸血症采用天然低蛋白限制饮食治疗,保证充足能量摄入以维持代谢平衡。天然蛋白是甲基丙二酸前体的来源,摄入量根据疾病的严重程度和临床病程进行个体化调整。欧洲中心的 MMA 治疗经验和方法存在差异,所开处方的天然蛋白和无旁路氨基酸的量不同,尽管无旁路氨基酸的使用似乎与治疗结果无关。对于早期接受 MMA 治疗的患者,需要进一步的长期预后数据。本病例研究报告了一名 MMA 女性患者从出生到 35 岁(包括妊娠)的长期病程和饮食治疗的终生变化,为这一疾病的长期预后提供了有价值的信息。低天然蛋白饮食(1.5-1.0g/kg/天)是治疗的基础,但在不同时期需要临时补充无旁路氨基酸、维生素-矿物质混合物和能量补充剂(在儿童期、青春期、成年期和妊娠期间)。儿童期精神运动发育稍有延迟,但在成年期仍处于正常范围内。仅有少数代谢失代偿发作需要静脉输注葡萄糖,但在 27 岁时,她在接受类固醇治疗后需要重症监护。在妊娠期间,她病情稳定,但接受了强化的生化和医学随访。本病例报告成功地对一名 MMA 患者进行了从儿童期到整个妊娠、分娩和产后的长期随访,证实了仔细的临床、生化和饮食监测对于确保 MMA 患者获得良好结局至关重要。根据个体临床病程,需要进行个体化治疗。了解长期治疗和临床结局是影响未来 MMA 临床指南的重要信息。